Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

By sjmartinez • June 20, 2024

Armstrong AW, Alexis AF, Blauvelt A, Silverberg JI, Feeney C, Levenberg M, Chan G, Zhang F, Fostvedt L. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Jun 19. doi: 10.1007/s13555-024-01183-3. Epub ahead of print. PMID: 38896380.

Tags: Dermatology, Publications

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients[...]

Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States

Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Gender differences in pain interference with daily activities and functional impairment[...]

Artificial Intelligence and Dermatology

Wongvibulsin S, Lee I. Artificial Intelligence and Dermatology. JAMA Dermatol. 2025 Jan 8. doi: 10.1001/jamadermatol.2024.4645. Epub ahead of print. PMID: 39774621.